Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2011

Oct 11, 2011

29977_dirs_2011-10-11_bd04aea4-4b55-46bf-aaf8-f7baece2d744.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2011-10-10

Reporting Person: Terifay Robert J (SVP Commercial)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-10-10 Common Stock M 20000 $21.34 Acquired 20000 Direct
2011-10-10 Common Stock F 6588 $64.78 Disposed 13412 Direct
2011-10-10 Common Stock F 6198 $64.78 Disposed 7214 Direct
2011-10-10 Common Stock M 9372 $21.34 Acquired 16586 Direct
2011-10-11 Common Stock S 402 $64.98 Disposed 16184 Direct
2011-10-11 Common Stock S 6812 $65.34 Disposed 9372 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-10-10 Incentive Stock Option (right to buy) $21.34 M 9372 Disposed 2017-02-26 Common Stock (9372) Direct
2011-10-10 Non-Qualified Stock Option (right to buy) $21.34 M 20000 Disposed 2017-02-26 Common Stock (20000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1387 Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 402 shares of Company stock on October 11, 2011 at prices ranging from $64.97 to $64.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the trust on October 11, 2011 at each separate price.

F3: Represents volume-weighted average price of sales of 6,812 shares of Company stock on October 11, 2011 at prices ranging from $65.06 to $65.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the trust on October 11, 2011 at each separate price.

F4: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F5: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.